Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 18/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13553669 | 0.94 | TNK2 (0.47) | TNK2SRC | |
| SCHEMBL14682000 | 0.91 | RIPK2 (0.42) | TNK2SRCPAK4PKN1 | |
| SCHEMBL15036024 | 0.79 | TNK2 (0.48) | TNK2SRCPAK4PKN1 | |
| SCHEMBL15041508 | 0.79 | TNK2 (0.48) | TNK2SRCPAK4PKN1 | |
| SCHEMBL15034859 | 0.78 | TNK2 (0.48) | TNK2SRC | |
| SCHEMBL15036085 | 0.77 | JAK3 (0.41) | TNK2SRC | |
| SCHEMBL14681946 | 0.77 | TNK2 (0.39) | TNK2SRCPAK4PKN1 | |
| SCHEMBL13553499 | 0.76 | FGFR1 (0.38) | TNK2SRCPAK4PKN1 | |
| SCHEMBL15041482 | 0.75 | TNK2 (0.42) | TNK2SRCPAK4PKN1 | |
| SCHEMBL14681967 | 0.74 | PAK3 (0.45) | TNK2SRCPAK4PKN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | TNK2 7/4885SRC 26/4885PAK4 5/4885 |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | PAK2, PAK1, PAK6 | TNK2 9/4885SRC 115/4885PAK4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.